RhoVac AB has been granted 2.5 million euro from Horizon 2020
RhoVac AB ("RhoVac") announces today, 22th August 2019, that the EU Commission grants 2.5 million euro to RhoVac, from the research and innovation program Horizon 2020.The grant from the EU framework program Horizon 2020 runs over 36 months and supports the company's further development of the RV001 project for prostate cancer treatment, as well as continued business development with the aim of reaching an agreement with a future partner. In its assessment, the Commission finds the company's development plans well thought-out and realistic. The Commission emphasizes that the RV001 project